Our team of experts is committed to making GB-13 — our targeted immunotoxin — available in the toolbox of every neurosurgeon and neuro-oncologist.
CEO, Chair - Board of Directors
Sil started his career at Deliotte & Touche in audit and corporate finance positions. Since then, he has brought an entrepreneurial spirit to a number of start-ups in the early drug development space. His experiences include executive level managerial and business development roles with companies developing cancer and inflammatory therapies and iron replacement therapies. He has successfully negotiated in and out license agreements with academic institutions, and both private and public biotech companies.
Lynn Maines, PhD
Co-founder, Business Development and Operations Advisor
Dr. Maines brings over 25 years of drug development experience to the team. He is the Vice President for Research and Business Affairs at Apogee Biotechnology Corporation. He has experience in all facets of drug development, previously leading regulatory efforts to successfully advance new drugs into and through clinical trials as well as executing out-licensing agreements with these drugs.
Dr. Maines received his Ph.D. in Pharmacology and MBA from the Pennsylvania State University.
Randy Schrecengost, PhD
Chief Scientific Officer
Dr Schrecengost brings 20 years of cancer research to the team with more than a decade focusing on drug discovery and development. He has been with Targepeutics since 2020 and has lead orphan drug designation approval for the lead platform and successfully applied for SBIR grant funding. Randy oversees all aspects of research at Targepeutics and facilitates and manages collaborative research projects at multiple research institutions.
Prior to joining Targepeutics, he was Senior Scientist at Apogee Biotechnology Company where he managed the prostate cancer research program. His work was instrumental in moving the lead compound forward into prostate cancer clinical trials.
Dr Schrecengost received his PhD in Microbiology from the University of Virginia and completed a post-doctoral fellowship (studying prostate cancer) at Thomas Jefferson University.